title: Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
abstract: Human-mouse chimeric immunoglobulins G1 and G3 (IgG1 and IgG3) (ChG1, ChG3) and "complementarity-determining region"-grafted, humanized IgG1 and IgG3 (HuG1, HuG3) constructs of the mouse monoclonal antibody (mAb) M195 were characterized. M195 is a murine immunoglobulin G2a (IgG2a), anti-CD33 mAb, specifically reactive with acute myelogenous leukemia cells, that is active as an antileukemia agent in humans. The new mAb constructs maintained specificity and biological function, including rapid internalization after binding to the cell surface, which has been important for delivery of therapeutic isotopes in patients. Although previously reported complementarity-determining region-grafted mAbs had reduced avidities, the HuG1 and HuG3 M195 showed up to an 8.6- and 4-fold higher binding avidity, respectively, than the original murine mAb. All constructs were effective at mediating rabbit complement-mediated cytotoxicity against HL60 targets. Fibroblasts transfected with CD33 genes and expressing high levels of CD33 antigen were also lysed in the presence of human complement, but HL60 cells or fibroblasts with lower CD33 levels were not killed. Thus, the inability of M195 and constructs to kill HL60 targets with human complement is due to the much lower antigen density on HL60 cells compared to CD33+ fibroblasts. Unlike the murine M195, the chimeric and humanized M195 demonstrated antibody-dependent cell-mediated cytotoxicity using human peripheral blood mononuclear cells as effectors. Because the chimeric and humanized M195 have improved avidities as compared to the original M195 and have, in addition, the potential to avoid human anti-mouse antibody responses and to recruit human effector functions, these new constructs may be useful therapeutically, either alone or conjugated to toxins or isotopes, in the treatment of acute myelogenous leukemia.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
authors.forename: P C
authors.initials: PC
authors.lastname: Caron
authors.forename: M S
authors.initials: MS
authors.lastname: Co
authors.forename: M K
authors.initials: MK
authors.lastname: Bull
authors.forename: N M
authors.initials: NM
authors.lastname: Avdalovic
authors.forename: C
authors.initials: C
authors.lastname: Queen
authors.forename: D A
authors.initials: DA
authors.lastname: Scheinberg
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000918:Antibody Specificity; D015703:Antigens, CD / Q000032:analysis / Q000276:immunology*; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis / Q000276:immunology*; D001667:Binding, Competitive; D003602:Cytotoxicity, Immunologic; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D011869:Radioligand Assay; D063268:Sialic Acid Binding Ig-like Lectin 3
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; C571165:Cd33 protein, mouse; D063268:Sialic Acid Binding Ig-like Lectin 3